Business
Derrell D. Porter, M.D., Elected to Board of Directors of Passage Bio
PHILADELPHIA, June 01, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing
About this update from Passage Bio, Inc.
[{"type":"text","content":"PHILADELPHIA, June 01, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced the election of Derrell D. Porter, M.D., to its board of directors and his appointment to the Audit Committee, effective as of May 27, 2021, the date of Passage Bio’s Annual Meeting of Stockholders. Dr. Porter is founder and chief executive officer of Cellevolve Bio, a cell therapy company focused on transforming investigational CNS, oncology and transplant therapies into commercial products. “With his strong corporate strategy, product development and commercial experience, Derrell is a terrific addition to our board,” said Bruce Goldsmith, Ph.D., president and chief executive officer of Passage Bio. “His election further strengthens our board, adding valuable insights as we continue to develop and implement strategies to deliver potentially transformative therapies to patients around the world.” Tadataka Yamada, M.D., chairman of the Passage Bio Board of Directors, said: “We are delighted to welcome Derrell to the Passage Bio Board of Directors and Audit Committee, and we look forward to working with him and benefiting from his wealth of industry experience.” Prior to founding and leading Cellevolve Bio in 2020, Dr. Porter served as senior vice president and head of Commercial at Atara Biotherapeutics, Inc. from May 2017 to October 2019. While there, he built the global commercial organization, including its product launch strategy. Prior to joining Atara, Dr. Porter served as a vice president with Gilead Sciences from April 2013 to May 2017, where he was responsible for corporate strategy, commercial planning, and global launch preparation for all of Gilead’s therapeutic areas. Previously, Dr. Porter was at AbbVie and Amgen, where he served in multiple U.S., EU and global roles of increasing responsibility in strategy, corporate development, business unit management, and sales and marketing. Dr. Porter began his career at McKinsey & Company in Los Angeles as part of the West Coast Health Care Practice. He currently serves on the boards of directors of several private companies. Dr. Porter holds an M.D. and an MBA from the University of Pennsylvania, and a bachelor’s degree in psycho...